1 苏晖, 江开达, 徐一峰. 5-羟色胺与去甲肾上腺素再摄取抑制药是焦虑障碍的一线治疗药物. 中国新药与临床杂志, 2010, 4:264-269
2 Lam WY, Fresco P. Medication Adherence Measures:An Overview. BioMed Research International, 2015. 1-12
3 Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment:three decades of research. A comprehensive review. J Clin Pharm Ther, 2001, 26(5):331-342
4 Karve S, Cleves MA, Helm M, et al. Good and poor adherence:optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin, 2009, 25(9):2303-2310
5 MS Kirkman, MT Rowan-Martin, R Levin, et al. Determinants of Adherence to Diabetes Medications:Findings From a Large Pharmacy Claims Database. Diabetes Care, 2015, 38 (4):604-609
6 王琰, 何燕玲, 王静夷, 等. 上海和北京及长沙三个城市焦虑障碍和抑郁症的大众知晓度调查. 中华精神科杂志, 2015, 48(4):220-226
7 吴秋霞, 陈淑宝, 罗小阳, 等. 综合医院非精神科医师对广泛性焦虑障碍的知晓情况调查. 中国临床心理学杂志, 2016, 24(5):894-899
8 SL Thier, KS Yu-Isenberg, BF Leas, et al. In Chronic Disease, Nationwide Data Show Poor Adherence by Patients to Medication And by Physicians to Guidelines. Managed Care, 2008, 2(17):48-57
9 Skes MLM. Measurement adherence to therapy by MPR(Medication Possession Ratio). European Journal of Public Health, 2015, 3(25):440
10 Rolnick SJ, Pawloski PA, Hedblom BD, et al. Patient Characteristics Associated with Medication Adherence. Clinical Medicine & Research, 2013, 11(2):54-65
11 宋乐鸥, 季建林. 精神科与心理咨询门诊焦虑障碍患者就诊情况分析. 临床心身疾病杂志, 2006, 3:197-200
|